Evolution of the Average Target: Sanofi

Data source: Sanofi(SAN)

Evolution of the Target Price: Sanofi

Data source: Sanofi(SAN)

Changes in Analyst Recommendations: Sanofi

Data source: Sanofi(SAN)
b2ee462f6.CAvsUcBKKg8uMTZcl3Nr9oOYISKcg4zU_3iFco8mT9Y.P0y4EqYoenZLcGxv4Bkvu7fQREns5uW-izXjSthoCIFmRYQ2gh5YN11Lbw~506abb34f28fef6141cfba22920a4d6c
09-29 Regeneron Needs 'Better' Terms in Sanofi Renegotiation, RBC Says MT
09-29 Sanofi : Buy rating from Deutsche Bank ZD
09-17 Sanofi : UBS reiterates its Neutral rating ZD
09-15 Sanofi : Deutsche Bank reiterates its Buy rating ZD
09-14 Sanofi : Deutsche Bank reiterates its Buy rating ZD
09-09 RBC Capital Markets Begins Sanofi's Coverage at Sector Perform MT
09-09 RBC Initiates Sanofi at Sector Perform With EUR80 Price Target MT
09-09 RBC Launches Sanofi Coverage at Sector Perform Amid Management Turnaround, 'Light' Near-term Catalysts MT
09-08 Sanofi : From a Buy to Neutral rating by RBC ZD
09-08 Sanofi : Barclays is Neutral ZD
09-02 Sanofi : Gets a Buy rating from Deutsche Bank ZD
09-01 Regeneron Seen Weighing Expanded Sanofi Deal, RBC Says MT
08-25 Sanofi : Deutsche Bank reiterates its Buy rating ZD
08-24 Sanofi : Berenberg gives a Buy rating ZD
08-24 Berenberg Keeps Sanofi at Buy Ahead of Asthma Drug Phase 2b Trial Results MT
08-24 Berenberg Still Rates Sanofi a Buy Zonebourse
08-20 Cancer vaccines finally garner the spotlight Alphavalue
08-19 Sanofi : Deutsche Bank reiterates its Buy rating ZD
08-19 Sanofi : UBS reiterates its Neutral rating ZD
08-14 AlphaValue still cautious about Sanofi Zonebourse
08-13 Sanofi: Q2 beat gets sidelined by burning pipeline issues Alphavalue
08-10 Nurix Therapeutics' STAT6 Degrader Likely to Receive Increased Recognition, RBC Says MT
08-10 Bernstein Expects Novo Nordisk to Continue Facing US GLP-1 Share Loss, Margin Pressure MT
08-07 Sanofi : Gets a Buy rating from Jefferies ZD
08-04 SANOFI : Bernstein remains its Buy rating ZD

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+12.17%
+4.37%
+5.91%
+4.29%
+7.46%
+5.11%
+28.35%
-7.72%
+4.87%
Average +7.20%
Weighted average by Cap. +7.93%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
72.64EUR
Average target price
94.06EUR
Spread / Average Target
+29.49%
High Price Target
112.00EUR
Spread / Highest target
+54.19%
Low Price Target
78.00EUR
Spread / Lowest Target
+7.38%

Analyst Consensus Detail

Consensus revision (last 18 months)

Trader
Investor
Global
Quality
ESG MSCI
A